A first Phase 2b study to investigate the safety and efficacy of the optimal dose range of PQ912 in early AD patients
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2019
Price : $35 *
At a glance
- Drugs PQ 912 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SAPHIR 2
- Sponsors Vivoryon Therapeutics
- 29 Aug 2019 According to a Vivoryon Therapeutics AG media release, trial initiation is anticipated in the first quarter of 2020 with the topline results expected in the second half of 2022.
- 19 Jul 2019 Status changed from planning to recruiting, according to a Vivoryon company website.
- 29 Nov 2018 According to a Probiodrug media release, presented the detailed study design of the Phase 2b core program of PQ-912 which incorporated the newest FDA and EMA draft guidance for early AD trials.